Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  ISIS Pharmaceuticals, Inc.    ISIS

SummaryChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets

ISIS Pharmaceuticals, Inc. : ISIS, YHOO, MU and INTC added to Nasdaq Active Stock Watch List at EPR

share with twitter share with LinkedIn share with facebook
share via e-mail
0
06/25/2013 | 03:05pm CET

New York, NY -- (ACCESSWIRE) --06/25/2013-- Equity Profile Report initiates a NASDAQ Active Stock Watch List adding Isis Pharmaceuticals, Inc. (NASDAQ:ISIS), Yahoo! Inc. (NASDAQ:YHOO), Micron Technology Inc. (NASDAQ:MU) and Intel Corporation (NASDAQ:INTC)

Isis Pharmaceuticals, Inc. (NASDAQ:ISIS) a leading company in antisense drug discovery and development finished their previous session (+29.24%) on 9,784,879 shares traded. They recently announced that the data they received from the PHASE 2 study of ISIS-APOCIIIRx in patients with high triglycerides and type 2 diabetes was very positive. They are currently us (+275.93%) from its recent 52-week low which has prompted Equity Profile Report to add the stock to their NASDAQ Active Stock Watch List and Investor Poll.

To find out what other Investors are saying about Isis Pharmaceuticals, Inc. (NASDAQ:ISIS)

Click Here: http://www.equityprofilereport.com/Survey.aspx?stock=ISIS&SubId=AW

Yahoo! Inc. (NASDAQ:YHOO) ?a company that provides search, content and communication tools via the web and mobile devices around the world finished their previous session (-4.47%) on 37,007,539. They recently announced that they have completed their acquisition of Tumblr, who are one of the fastest growing media networks in the world. This acquisition is expected to grow Yahoo?s audience by more than one billion monthly visitors. This news has prompted Equity Profile Report to add Yahoo! Inc. (NASDAQ:YHOO) to their NASDAQ Active Stock Watch List and Investor Poll.

To find out what other Investors are saying about Yahoo! Inc. (NASDAQ:YHOO)

Click Here: http://www.equityprofilereport.com/Survey.aspx?stock=YHOO&SubId=AW

Also mentioned in Equity Profile Report?s Active Stock Watch List and Investor Poll was: Micron Technology Inc. (NASDAQ:MU), Intel Corporation (NASDAQ:INTC), ARM Holdings plc (NASDAQ:ARMH) and NetApp, Inc. (NASDAQ:NTAP)

To see what other investors are saying about: MU, INTC, ARMH and NTAP

Click here: http://www.equityprofilereport.com/PR.aspx?stock=MU-INTC-ARMH-NTAP&SubId=AW

EquityProfileReport.com monitors and scans the markets for stock related signals as well as any external factors that might bring trading opportunities. Through a vast network of IR professionals EquityProfileReport.com is often aware of several large investor awareness campaigns being deployed. Timing is important when trading Small Caps and Penny Stocks.

Simply sign up for free and start receiving exclusive alerts.

Subscribe Here:http://www.EquityProfileReport.com

Disclosure: EquityProfileReport.com is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell securities. Investors should always conduct their own due diligence with any potential investment. Please visit EquityProfileReport.com website, for complete risks and disclosures.

Contact Info:

Equity Profile Report
[email protected]


© Accesswire 2013
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on ISIS PHARMACEUTICALS, INC.
01/19 IONIS PHARMACEUTICALS INC : Change in Directors or Principal Officers (form 8-K)
01/19 IONIS PHARMACEUTICALS : ' Inotersen NDA Accepted for Priority Review by the FDA
01/08 AKCEA THERAPEUTICS : Initiates Phase 2b Study of -APOCIII-LRx in Patients with H..
01/08 IONIS PHARMACEUTICALS : ' Inotersen NDA Accepted for Priority Review by the FDA
01/06 AKCEA THERAPEUTICS : Initiates Phase 2b Study of -APOCIII-LRx in Patients with H..
2017 IONIS PHARMACEUTICALS : begins clinical study of oral antisense GI drug
2017 BIOGEN : and Ionis Enter into New Collaboration to Identify Novel Therapies for ..
2017 IONIS PHARMACEUTICALS : Announces The Initiation Of A Clinical Study Of Its Firs..
2017 IONIS PHARMACEUTICALS : Announces the Initiation Of A Clinical Study Of Its Firs..
2017 IONIS PHARMACEUTICALS : Pharma begins clinical study of -JBI1-2.5Rx, an orally d..
More news
News from SeekingAlpha
2015 Game Plan For The Week - Cramer's Mad Money (12/18/15)
2015 PREMARKET BIOTECH DIGEST : Portola's Milestone, Shkreli Resigns, BioMarin DMD Dr..
2015 Isis Pharma has had enough, name changed to Ionis Pharmaceuticals
2015 Bear Afoot? No Recession Needed For A Possible Sighting
2015 PREMARKET BIOTECH DIGEST : Gilead's Upside, Shire-Baxalta Deal, ARIAD Lowers Gui..
Financials ($)
Sales 2017 447 M
EBIT 2017 32,0 M
Net income 2017 -20,4 M
Finance 2017 310 M
Yield 2017 -
P/E ratio 2017 -
P/E ratio 2018 160,81
EV / Sales 2017 13,7x
EV / Sales 2018 11,8x
Capitalization 6 429 M
Chart ISIS PHARMACEUTICALS, INC.
Duration : Period :
ISIS Pharmaceuticals, Inc. Technical Analysis Chart | ISIS | US4643301090 | 4-Traders
Income Statement Evolution
Consensus
 
Mean consensus HOLD
Number of Analysts 14
Average target price 57,1 $
Spread / Average Target 10%
EPS Revisions
Managers
NameTitle
Stanley T. Crooke Chairman, President & Chief Executive Officer
Brett P. Monia Chief Operating Officer
Elizabeth L. Hougen CFO, Principal Accounting Officer & SVP-Finance
B. Lynne Parshall Director
Joseph H. Wender Independent Outside Director
Sector and Competitors
1st jan.Capitalization (M$)
ISIS PHARMACEUTICALS, INC.-6.12%6 429
CELLTRION, INC.--.--%32 824
IQVIA HOLDINGS INC5.21%21 389
LONZA GROUP2.62%20 968
INCYTE CORPORATION-1.64%19 854
ALNYLAM PHARMACEUTICALS, INC.-1.75%12 881